ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Conferees Ok NCI Appropriations At $691.7 Million; Final Amount Available Won’t Be Set Until Spring

November 29, 1974

Smokers’ Quitlines Work, California Study Finds

October 25, 2002

Mace Rothenberg Leaves Vanderbilt For Pfizer Oncology.

November 14, 2008

NCI Programs: Seven Win Awards For Cancer Genetics Network, Informatics

July 31, 1998

Advisors tell NCI to rethink contracts for clinical trials cooperative group tissue banks

November 21, 2003

Clinical Trials Approved By NCI’s CTEP Listed

February 25, 2005